All In Biotech

Drug Trial Radar · NCT06810791

HVA vs IA/DA or VA in the Treatment of ND HR-AML

The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study

Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 876 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

876

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangzhou First People's Hospital; Guangdong Second Provincial General Hospital; Jiangmen Central Hospital; Shenzhen Second People's Hospital; First Affiliated Hospital of Guangxi Medical University; Dongguan People's Hospital; First People's Hospital of Foshan; Guangdong Provincial Hospital of Traditional Chinese Medicine; Huizhou Municipal Central Hospital; Shenzhen Hospital of Southern Medical University; Affiliated Hospital of Guangdong Medical University; People's Hospital of Guangxi Zhuang Autonomous Region; First People's Hospital of Chenzhou; Hunan Provincial People's Hospital; Ganzhou City People's Hospital; First Affiliated Hospital of Gannan Medical University
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.

Conditions

  • Newly Diagnosed Acute Myeloid Leukemia With High Risk

Interventions

  • HVADrug

    Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14. Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.

  • VADrug

    VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.

  • Standard ChemotherapyDrug

    Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite complete remission (CRc)Time frame: At the end of cycle 2 (each cycle is 28 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Hematology,Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.